Biomarkers in mood disorders research: developing new and improved therapeutics
DOI:
https://doi.org/10.1590/0101-60830000000027Abstract
Background Recently, surrogate neurobiological biomarkers that correlate with target engagement and therapeutic response have been developed and tested in early phase studies of mood disorders. Objective The identification of biomarkers could help develop personalized psychiatric treatments that may impact public health. Methods These biomarkers, which are associated with clinical response post-treatment, can be directly validated using multimodal approaches including genetic tools, proteomics/metabolomics, peripheral measures, neuroimaging, biostatistical predictors, and clinical predictors. Results To date, early phase biomarker studies have sought to identify measures that can serve as “biosignatures”, or biological patterns of clinical response. These studies have also sought to identify clinical predictors and surrogate outcomes associated with pathophysiological domains consistently described in the National Institute of Mental Health’s (NIMH) new Research Domain Criteria (RDoC). Using the N-methyl-D-aspartate (NMDA) antagonist ketamine as an example, we identified changes in several domains (clinical, cognitive, and neurophysiological) that predicted ketamine’s rapid and sustained antidepressant effects in individuals with treatment-resistant major depressive disorder (MDD) or bipolar depression. Discussion These approaches may ultimately provide clues into the neurobiology of psychiatric disorders and may have enormous impact Backon the development of novel therapeutics.Downloads
Download data is not yet available.
Downloads
Published
2014-01-01
Issue
Section
Point of View
License
Once accepted for publication, the manuscript becomes permanent property of the Archives of Clinical Psychiatry. This copyright transfer subsumes exclusive and unlimited entitlement of the Archives of Clinical Psychiatry to publish and distribute the full contents of articles in whichever publishing medium, including press and electronic media, in Brazil and abroad.
Manuscripts are accepted with the understanding that the Editor and the editorial staff have the right to make revisions aimed at greater conciseness, clarity, and conformity with Journal style, of course without changing its content.
How to Cite
Biomarkers in mood disorders research: developing new and improved therapeutics . (2014). Archives of Clinical Psychiatry, 41(5), 131-134. https://doi.org/10.1590/0101-60830000000027